-
ASCO China Voice | Prof. Haiqiang Mai: Domestic PD-L1 Inhibitor Tagitinlimab Shows New Strength as First-Line Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a malignancy with high prevalence in Southern China and other Southeast Asian countries, imposing a significant disease burden. Treatment options for recurrent/metastatic NPC (R/M NPC) remain limited. In recent years, immune checkpoint inhibitors (ICIs) have brought new hope to this patient population, and domestically developed ICIs in China have demonstrated promising…
-
National Open Day Event at the National Key Laboratory of Hematology and Health, 2025
In celebration of the 2025 National Science and Technology Workers Day and International Children’s Day, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College hosted a public science outreach event as part of the National Open Day at the National Key Laboratory of Hematology and Health. Over…
-
ASCO China Voice | Prof. Yehui Shi: Utidelone Combination Offers New Hope for Patients with HER2-Negative Breast Cancer and Brain Metastases
This study addresses the current lack of effective systemic treatments for HER2-negative brain metastases, a particularly challenging subtype where standard therapies offer limited benefit due to the restrictive nature of…
-
ASCO China Voice | Prof. Yan Huang’s Team Reports Phase I Results of BL-B01D1, Paving a New Path in Precision Therapy for SCLC
At the ongoing 2025 ASCO Annual Meeting, Professor Yan Huang from Sun Yat-sen University Cancer Center delivered an oral presentation (Abstract #3002) on the results of a Phase I study…
-
ASCO China Voice | Prof. Kefeng Ding: ANCHOR Study Offers a New First-Line Treatment Option for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Oncology Frontier: Could you share the background and design rationale of the ANCHOR study? Prof. Kefeng Ding: In our previous Phase II single-arm exploratory trial, we observed that the combination…
-
Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation
The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global…
Connecting Medical Expertise through Media
